← All trials
NCT04043676
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2019
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundación Teófilo Hernando, SpainLead sponsor
- Universidad Complutense de MadridOverall official - principal investigator
- University of SevilleOverall official - principal investigator
- University of SalamancaOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Hospital Universitario Ramon y CajalOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- Mario Negri InstituteOverall official - principal investigator
- University of MalagaOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.